Skip to content
Company Analysis

Regencell Bioscience Holdings L RGC

A comprehensive view of key metrics, scores, and financial health for Regencell Bioscience Holdings L

Overview of Regencell Bioscience Holdings Limited

RGC NCM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Large Cap
Regencell Bioscience Holdings Limited (RGC), is a Large Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $20.31, about 0.0% overvalued vs fair value, +24.0% 1Y return, ranked 343/979 in sector.
Metrics ROE -54.8%
USD 20.31
-5.05%
(Delayed)
• Vol 90d: 111.8%
52-Week Range
Market Cap
$10.06B
Enterprise Value
$10.06B
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 43%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.regencellbioscienc...
HQ Causeway Bay
Employees 10
Fiscal year Jun 30

Next Events

Earnings Jun 2 Estimated

Fair Value Snapshot

Insufficient data
Show more details
  • Revenue data missing or non-positive

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$0
Gross Profit
$-392.7K
47.3%%
R&D Expense
$948.3K
-11.1%%
Operating Income (EBIT)
$-3.6M
24.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Regencell Bioscience Holdings L's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
31
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
0
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 44% Coverage
Trade-Off Triangle Visualization A ternary plot showing RGC's balance between Growth (32.6%), Profitability (19.1%), and Safety (48.3%). Growth 33% Safety 48% Profitability 19%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

- vs peers
-
Key Signals
EPS Growth YoY 26.7% 49p
Strengths
  • Current Ratio in top 20% of peers (7.39, 95th percentile)
  • Quick Ratio in top 20% of peers (42.71, 99th percentile)
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

19th percentile vs peers
19
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

49th percentile vs peers
49
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Regencell Bioscience Holdings L.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000